EWA
MLYS icon

EverSource Wealth Advisors’s Mineralys Therapeutics MLYS Stock Holding History

EverSource Wealth Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.31K Buy
196
+42
+27% +$1.23K ﹤0.01% 3238
2025
Q4 		$5.59K Buy
154
+2
+1% +$80 ﹤0.01% 3085
2025
Q3 		$5.76K Sell
152
-205
-57% -$4.43K ﹤0.01% 3095
2025
Q2 		$4.83K Buy
357
+341
+2,131% +$4.94K ﹤0.01% 3173
2025
Q1 		$254 Buy
+16
New +$184 ﹤0.01% 3646

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

EverSource Wealth Advisors's MLYS Position: Q1 2026 in Review

EverSource Wealth Advisors increased its Mineralys Therapeutics (MLYS) stake by 27% in Q1 2026, buying an estimated $1.23K and bringing the position to 196 shares worth $5.31K. The position accounts for ﹤0.01% of the portfolio, ranked #3238.

EverSource Wealth Advisors first reported a position in MLYS in Q1 2025 and has held it in 5 quarters since. The position peaked at $5.76K in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • EverSource Wealth Advisors held 196 shares of Mineralys Therapeutics worth $5.31K as of Q1 2026.
  • EverSource Wealth Advisors bought 42 Mineralys Therapeutics shares in Q1 2026, an estimated $1.23K.
  • Mineralys Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #3238 holding.
  • EverSource Wealth Advisors first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • EverSource Wealth Advisors's Mineralys Therapeutics position peaked at $5.76K in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.